CD38 antibody added to PI-IMiD-dex (quadruplet induction)
Adding a CD38 antibody to the standard three-drug induction roughly halves progression risk in newly diagnosed myeloma.
PERSEUS (Dara-VRd, HR 0.42), CEPHEUS (HR 0.57), IMROZ (Isa-VRd, HR 0.60), MAIA (Dara-Rd, OS HR 0.68). Quadruplets are standard regardless of transplant eligibility.
PERSEUS, with the earlier GRIFFIN and CASSIOPEIA trials, made a four-drug daratumumab quadruplet the standard for fit patients heading to transplant. It also introduced MRD-directed stopping of the antibody, a step towards treatment that is deep but not indefinite. Whether transplant itself remains necessary on top of a quadruplet is now the open question.
MAIA made a daratumumab-based triplet the standard first treatment for older or frail myeloma patients, replacing Rd alone. It proved an anti-CD38 antibody could improve survival, not just delay progression, when used up front. Quadruplets built on this backbone are now being tested in the same population.
Pages like this
not linked directly; found by shared links- Key paperCEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint
Shares CEPHEUS, IMROZ, MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant, Bortezomib.
- TargetCD38
Shares Isatuximab, MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant, PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma, Daratumumab.
- IdeaMRD-guided treatment-free intervals in myeloma
Shares PERSEUS, Daratumumab, Lenalidomide, Multiple myeloma.
- PersonPaul G. Richardson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- PersonKenneth C. Anderson
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TermMRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)
Shares PERSEUS, MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant, PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma, Multiple myeloma.
- TermVRd and Dara-VRd (myeloma induction regimens)
Shares Bortezomib, Daratumumab, Lenalidomide, Multiple myeloma.
- TermMGUS and smouldering myeloma
Shares Daratumumab, Lenalidomide, Multiple myeloma.